Literature DB >> 10517368

Assay of 6-mercaptopurine and its metabolites in patient plasma by high-performance liquid chromatography with diode-array detection.

Y Su1, Y Y Hon, Y Chu, M E Van de Poll, M V Relling.   

Abstract

A reversed-phase high-performance liquid chromatography (HPLC) method was developed to determine 6-mercaptopurine (MP) and seven of its metabolites (6-thioguanine, 6-thioxanthine, 6-mercaptopurine riboside, 6-thioguanosine, 6-thioxanthine riboside, 6-methylmercaptopurine and 6-methylmercaptopurine riboside) simultaneously in human plasma. A volume of 100 microl of plasma was used. Protein was removed from the sample by a simple and easy ultrafiltration step and ultrafiltrate was directly injected onto the HPLC system. Analytes were detected and confirmed with a diode-array detector before quantitation at 295 and 330 nm. The limit of detection for the analytes ranged from 20 to 50 nM. For the majority of patients receiving a 1 g/m2 MP intravenous infusion, MP and all metabolites except 6-thioguanine and 6-methylmercaptopurine riboside were present. This method serves as useful tool to characterize pharmacokinetics and pharmacodynamics of MP in oncology patients, and the small volume of plasma lends itself to pediatric studies.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10517368     DOI: 10.1016/s0378-4347(99)00311-4

Source DB:  PubMed          Journal:  J Chromatogr B Biomed Sci Appl        ISSN: 1387-2273


  13 in total

1.  Comparison of self-report and electronic monitoring of 6MP intake in childhood ALL: a Children's Oncology Group study.

Authors:  Wendy Landier; Yanjun Chen; Lindsey Hageman; Heeyoung Kim; Bruce C Bostrom; Jacqueline N Casillas; David S Dickens; William E Evans; Kelly W Maloney; Leo Mascarenhas; A Kim Ritchey; Amanda M Termuhlen; William L Carroll; Mary V Relling; F Lennie Wong; Smita Bhatia
Journal:  Blood       Date:  2017-02-02       Impact factor: 22.113

2.  Transporter-mediated protection against thiopurine-induced hematopoietic toxicity.

Authors:  Partha Krishnamurthy; Matthias Schwab; Kazumasa Takenaka; Deepa Nachagari; Jessica Morgan; Mark Leslie; Weinan Du; Kelli Boyd; Meyling Cheok; Hiromitsu Nakauchi; Catia Marzolini; Richard B Kim; Balasubramanian Poonkuzhali; Erin Schuetz; William Evans; Mary Relling; John D Schuetz
Journal:  Cancer Res       Date:  2008-07-01       Impact factor: 12.701

3.  Differential effects of thiopurine methyltransferase (TPMT) and multidrug resistance-associated protein gene 4 (MRP4) on mercaptopurine toxicity.

Authors:  Chengcheng Liu; Laura J Janke; Jun J Yang; William E Evans; John D Schuetz; Mary V Relling
Journal:  Cancer Chemother Pharmacol       Date:  2017-06-16       Impact factor: 3.333

4.  Mercaptopurine Ingestion Habits, Red Cell Thioguanine Nucleotide Levels, and Relapse Risk in Children With Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group Study AALL03N1.

Authors:  Wendy Landier; Lindsey Hageman; Yanjun Chen; Nancy Kornegay; William E Evans; Bruce C Bostrom; Jacqueline Casillas; David S Dickens; Anne L Angiolillo; Glen Lew; Kelly W Maloney; Leo Mascarenhas; A Kim Ritchey; Amanda M Termuhlen; William L Carroll; Mary V Relling; F Lennie Wong; Smita Bhatia
Journal:  J Clin Oncol       Date:  2017-03-24       Impact factor: 44.544

5.  Systemic Exposure to Thiopurines and Risk of Relapse in Children With Acute Lymphoblastic Leukemia: A Children's Oncology Group Study.

Authors:  Smita Bhatia; Wendy Landier; Lindsey Hageman; Yanjun Chen; Heeyoung Kim; Can-Lan Sun; Nancy Kornegay; William E Evans; Anne L Angiolillo; Bruce Bostrom; Jacqueline Casillas; Glen Lew; Kelly W Maloney; Leo Mascarenhas; A Kim Ritchey; Amanda M Termuhlen; William L Carroll; F Lennie Wong; Mary V Relling
Journal:  JAMA Oncol       Date:  2015-06       Impact factor: 31.777

6.  Simultaneous Determination of 6-Mercaptopurine and its Oxidative Metabolites in Synthetic Solutions and Human Plasma using Spectrophotometric Multivariate Calibration Methods.

Authors:  Mohammad-Hossein Sorouraddin; Mohammad-Yaser Khani; Kaveh Amini; Abdolhossein Naseri; Davoud Asgari; Mohammad-Reza Rashidi
Journal:  Bioimpacts       Date:  2011-06-09

7.  6MP adherence in a multiracial cohort of children with acute lymphoblastic leukemia: a Children's Oncology Group study.

Authors:  Smita Bhatia; Wendy Landier; Lindsey Hageman; Heeyoung Kim; Yanjun Chen; Kristine R Crews; William E Evans; Bruce Bostrom; Jacqueline Casillas; David S Dickens; Kelly W Maloney; Joseph P Neglia; Yaddanapudi Ravindranath; A Kim Ritchey; F Lennie Wong; Mary V Relling
Journal:  Blood       Date:  2014-05-14       Impact factor: 22.113

8.  Nonadherence to oral mercaptopurine and risk of relapse in Hispanic and non-Hispanic white children with acute lymphoblastic leukemia: a report from the children's oncology group.

Authors:  Smita Bhatia; Wendy Landier; Muyun Shangguan; Lindsey Hageman; Alexandra N Schaible; Andrea R Carter; Cara L Hanby; Wendy Leisenring; Yutaka Yasui; Nancy M Kornegay; Leo Mascarenhas; A Kim Ritchey; Jacqueline N Casillas; David S Dickens; Jane Meza; William L Carroll; Mary V Relling; F Lennie Wong
Journal:  J Clin Oncol       Date:  2012-05-07       Impact factor: 44.544

Review 9.  Effect of ITPA Polymorphism on Adverse Drug Reactions of 6-Mercaptopurine in Pediatric Patients with Acute Lymphoblastic Leukemia: A Systematic Review and Meta-Analysis.

Authors:  Yeonhong Lee; Eun Jeong Jang; Ha-Young Yoon; Jeong Yee; Hye-Sun Gwak
Journal:  Pharmaceuticals (Basel)       Date:  2022-03-29

10.  Individual prediction of nonadherence to oral mercaptopurine in children with acute lymphoblastic leukemia: Results from COG AALL03N1.

Authors:  Anna L Hoppmann; Yanjun Chen; Wendy Landier; Lindsey Hageman; William E Evans; F Lennie Wong; Mary V Relling; Smita Bhatia
Journal:  Cancer       Date:  2021-06-23       Impact factor: 6.921

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.